Dataset Information

Wound healing efficacy of novel ayurveda formulation- Pentabark Kashaya: In wistar rats using excision wound model- an in vivo study.

ABSTRACT:

Background

Wound healing plays a major concern in the field of surgery as it requires uneventful healing. Management aims towards prevention of infection and to accelerate healing. Acharya Sushruta has given more emphasis on Vrana (wound) and its chikitsa (treatment). Many antiseptic agents which prevent infection are widely used but have no role in accelerating the healing process and are cytotoxic, deleterious to wound healing. In this regard an innovative polyherbomineral formulation Pentabark Kashaya (PK)was formulated to assess acute dermal toxicity and woundhealing activity.

Objective

To explore the wound healing efficacy of novel Ayurveda Formulation i.e Pentabark Kashaya in Wistar rats using the excision wound model.

Materials and method

Acute dermal toxicity study was carried out on five female Wistar rats by following the OECD guideline 434 and signs of toxicity were assessed for the period of 14 days. Wound healing activitywas assessed on the excision wound model. 18 male Wistar rats were procured for the study and divided into three groups (n = 6 in each group). The test group was treated with application of PK, standard group with Povidone iodine solution 5% and control group with distilled water. The parameters assessed were epithelialization period, wound contraction rate, wound closure day and swab test for microbial load for the period of 21 days. Statistical analysis was done by using one way ANOVA and Tukeys HSD to assess changes in between three groups at each time point.

Results

No signs of acute dermal toxicity were seen, which proved that PK is safe for application. Significant results were seen in the parameters of wound healing like period of epithelialization and wound closure day. Percentage of wound contraction rate was increased in test group when compared to other groups. Histopathology of skin showed marked changes in re-epithelialization, dermal fibroblast, dermal fibrocytes in test group when compared to control group.

Conclusion

PK is safe for application and it is effective in wound healing.

Clinical trial registration no

Not applicable.

SUBMITTER: Madiwalar MB

PROVIDER: S-EPMC9307938 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Thymoquinone is a natural bioactive with significant therapeutic activity against multiple ailments including wound healing. The poor aqueous solubility and low skin permeability limit its therapeutic efficacy. The present investigation aimed to improve the biopharmaceutical attributes of thymoquinone to enhance its topical efficacy in wound healing. A nanoemulsion-based hydrogel system was designed and characterized as a nanotechnology-mediated drug delivery approach to improve the therapeutic efficacy of thymoquinone, utilizing a high-energy emulsification technique. The black seed oil, as a natural home of thymoquinone, was utilized to improve the drug loading capacity of the developed nanoemulsion system and reduced the oil droplet size to <100 nm through ultrasonication. The influence of formulation composition, and the ultrasonication process conditions, were investigated on the mean globule size and polydispersity index of the generated nanoemulsion. Irrespective of surfactant/co-surfactant ratio and % concentration of surfactant/co-surfactant mixture, the ultrasonication time had a significant (p < 0.05) influence on the mean droplet size and polydispersity index of the generated nanoemulsion. The developed nanoemulgel system of thymoquinone demonstrated the pseudoplastic behavior with thixotropic properties, and this behavior is desirable for topical application. The nanoemulgel system of thymoquinone exhibited significant enhancement (p < 0.05) in skin penetrability and deposition characteristics after topical administration compared to the conventional hydrogel system. The developed nanoemulgel system of thymoquinone exhibited quicker and early healing in wounded Wistar rats compared to the conventional hydrogel of thymoquinone, while showing comparable healing efficacy with respect to marketed silver sulfadiazine (1%) cream. Furthermore, histopathology analysis of animals treated with a developed formulation system demonstrated the formation of the thick epidermal layer, papillary dermis along with the presence of extensive and organized collagen fibers in newly healed tissues. The outcome of this investigation signifies that topical delivery of thymoquinone through nanoemulgel system is a promising candidate which accelerates the process of wound healing in preclinical study.

Project description:BackgroundWe recently reported the clinical safety profile of RJX, a well-defined intravenous GMP-grade pharmaceutical formulation of anti-oxidant and anti-inflammatory vitamins as active ingredients, in a Phase 1 study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105) (Uckun et al., Front. Pharmacol. 11, 594321. 10.3389/fphar.2020.594321). The primary objective of the present study was to examine the effects of GMP-grade RJX on wound and burn injury healing in diabetic rats.MethodsIn the present study, a rat model of T2DM was used that employs HFD in combination with a single injection of STZ intraperitoneally (i.p) at a moderate dose level (45 mg/kg). Anesthetized diabetic rats underwent full-thickness skin excision on the back or were subjected to burn injury via a heated brass probe and then started on treatments with normal saline (NS = vehicle) or RJX administered via intraperitoneal injections for three weeks.FindingsNotably, diabetic rats treated with the 1.25 mL/kg or 2.5 mL/kg RJX (DM+RJX groups) rapidly healed their wounds as fast as non-diabetic control rats. Inflammatory cell infiltration in the dermis along with fibrin and cell debris on the epithelial layer persisted for up to 14 days in the DM+NS group but not in RJX-treated groups. The histopathological score of wound healing on days 7 and 14 was better in diabetic rats treated with RJX than diabetic rats treated with NS and comparable to the scores for non-diabetic healthy rats consistent with an accelerated healing process. The residual wound area of RJX-treated rats was significantly smaller than that of NS-treated diabetic rats at each evaluation time point (P<0.001). The accelerating effect of RJX on diabetic wound healing was dose-dependent. We obtained similar results in the burn injury model. Our results demonstrate that RJX - at a dose level >10-fold lower than its clinical maximum tolerated dose (MTD) - accelerates the healing of excision wounds as well burn injury in diabetic rats.